Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines.
10.9758/cpn.2017.15.3.199
- Author:
Hee Ryung WANG
1
;
Won Myong BAHK
;
Jeong Seok SEO
;
Young Sup WOO
;
Young Min PARK
;
Jong Hyun JEONG
;
Won KIM
;
Se Hoon SHIM
;
Jung Goo LEE
;
Duk In JON
;
Kyung Joon MIN
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Review
- Keywords:
Depressive disorder;
Expert consensus;
Guideline;
KMAP-DD 2017;
Therapy
- MeSH:
Complement System Proteins;
Depression;
Depressive Disorder*;
Psychiatry;
Psychopharmacology
- From:Clinical Psychopharmacology and Neuroscience
2017;15(3):199-209
- CountryRepublic of Korea
- Language:English
-
Abstract:
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
